Background. Iron may play a central role in oxygen radical generation during myocardial ischemia and after reperfusion. Because conditions during ischemia may also liberate iron, we hypothesized that administration of the iron chelator deferoxamine during ischemia would result in improved functional and metabolic recovery after postischemic reperfusion.
Treatment With Deferoxamine During Ischemia Improves Functional and Metabolic
Recovery and Reduces Reperfusion-Induced Oxygen Radical Generation in Rabbit Hearts Randall E. Williams, MD; Jay L. Zweier, MD; and John T. Flaherty, MD Background. Iron may play a central role in oxygen radical generation during myocardial ischemia and after reperfusion. Because conditions during ischemia may also liberate iron, we hypothesized that administration of the iron chelator deferoxamine during ischemia would result in improved functional and metabolic recovery after postischemic reperfusion.
Methods and Results. Isolated, perfused rabbit hearts were studied by phosphorus-31 nuclear magnetic resonance spectroscopy. The hearts received one of three treatments: deferoxamine at the onset of 30 minutes of global ischemia (n =9), deferoxamine as a bolus followed by a continuous 15-minute infusion begun at reflow (n=9), or standard perfusate (n=7). Hearts treated with deferoxamine during ischemia showed better recovery of developed pressure than did control hearts (63.2+7.5% versus 41.2+±2.9% of baseline) (p=0.02) and better recovery of myocardial phosphocreatine content (92.4±10.3% versus 68.2+±4.5% of baseline, p<0.05). These functional and metabolic benefits were comparable to those obtained with deferoxamine treatment during early reperfusion. In 15 additional hearts, intraischemic treatment with deferoxamine resulted in no reduction in oxygen radical concentrations as measured on frozen tissue by electron paramagnetic resonance spectroscopy at end ischemia, but the treatment eliminated the reperfusion-induced increase of free radical generation observed in control hearts (2.9+0.01 versus 7.0+0.07 gM, p<0.001). The magnitude of reduction was similar to that when deferoxamine was given at the onset of reflow (2.4±+0.02 ,uM, p<0.001 versus control). Conclusions. These results demonstrate improved functional and metabolic recovery of myocardium treated with deferoxamine during ischemia, accompanied by a reduction in reperfusion-induced oxygen free-radical generation to the same degree as reflow treatment, confirming the importance of iron in the pathogenesis of myocardial reperfusion injury. (Circulation 1991; 83:1006 -1014 Ev vidence continues to accumulate that suggests a central role for oxygen free radicals in the pathogenesis of postischemic myocardial reperfusion injury.12 Support for the free radical hypothesis includes a number of studies showing beneficial effects of various oxygen free-radical scav-engers on improving reperfusion function, cellular metabolism, or reduction in infarct size.3-7 Likewise, using the technique of electron paramagnetic resonance spectroscopy (EPR), our laboratory and others have directly measured the presence of oxygen-centered free radicals in ischemic myocardium.8 This technique and the EPR measurement of oxygen radical adducts by spin trapping have been used to demonstrate a significant increase in free radical concentration during the early seconds of postischemic reperfusion. 8, 9 See p 1112 The superoxide anion (02-) probably initiates a sequence of chemical reactions that result in cell membrane destruction and, ultimately, myocardial cell death.2 It is not yet clear, however, whether the superoxide anion acts directly to induce membrane damage or whether irreversible injury is due to the generation of the more reactive hydroxyl radical species ( OH). The more reactive hydroxyl radical may be formed from superoxide and hydrogen peroxide in a two-step reaction termed the "superoxidedriven Fenton reaction"'10:
+Fe3+ -Fe2++02
Fe2++H202 -Fe3+ +OH-+ OH Ferric iron (Fe3+) is first reduced to ferrous iron (Fe24) by reacting with superoxide. Hydrogen peroxide, formed by the dismutation of the superoxide anion,"1 may then react with ferrous iron to generate the hydroxyl radical.
A central role for the Fenton reaction in vivo is suggested by the results of previous studies using the iron chelator deferoxamine as an additive to hypothermic cardioplegia in a cardiac surgery model612 or as a pretreatment in canine models of myocardial stunning1314 and acute myocardial infarction.1' We previously showed improved functional and metabolic recovery in isolated, perfused rabbit hearts receiving deferoxamine at the time of postischemic reflow in a normothermic global ischemia model. 16 Numerous sources of intracellular and extracellular iron have been proposed to catalyze the Fenton reaction in vivo, including cytochrome P-450 enzymes, myoglobin-bound iron, cellular ferritin-iron chelates, and vascular transferrin-iron chelates. [16] [17] [18] [19] [20] Because of the ability of deferoxamine to enter cells and because of its very high affinity for iron, we hypothesized that administration of deferoxamine during ischemia would result in a reduction in oxygen radical generation. We also hypothesized that improved functional and metabolic recovery after reflow would be seen with intraischemic deferoxamine treatment.
In the present study, deferoxamine administered at the onset of global ischemia in an isolated, perfused rabbit heart model was compared with deferoxamine administered at the onset of reflow and with administration of control vehicle. Phosphorus-31 nuclear magnetic resonance spectroscopy (NMR) allowed noninvasive assessment of myocardial energy metabolism during ischemia and reperfusion, thus allowing simultaneous assessment of ventricular function. In a separate experiment, similar treatment groups were compared with the control group by EPR to assess tissue concentrations of oxygen radicals produced at the end of ischemia and early after reflow.
Methods

Experimental Preparation
Studies conformed to the guiding principles of the American Physiological Society. Female New Zealand White rabbits (1-2 kg) were heparinized and anesthetized with i.p. pentobarbital. In less than 40 seconds, the hearts were excised, the aortas were cannulated, and retrograde perfusion was initiated at a constant pressure of 80 mm Hg. Modified Krebs-Ringer's bicarbonate buffer perfusate contained (mM) 117 NaCI, 6 KCl, 3 CaCl2, 1.0 MgSO4, 0.5 EDTA, 16.7 glucose, and 24 NaHCO3 and was continuously bubbled with a 95% 02/5% CO2 mixture.
Temperature of the perfusate was controlled, and heat loss was minimized with insulated lines. Effluent perfusate was allowed to collect in a water-jacketed bath, in which the hearts remained immersed throughout ischemia and reperfusion. The bath temperature was closely monitored and was maintained at 37°C throughout the experiment by perfusing the water-jacketed bath separately with temperaturecontrolled, nonbubbled perfusate. A sidearm in the perfusion line allowed separate infusion of test solutions directly into the heart. A potassium chloridefilled wick electrode was placed in the right ventricle and was connected to an SD-9 stimulator (Grass Instrument Co., Qunicy, Mass.) allowing ventricular pacing at 175 beats/min.
To assess contractile function, we inserted a fluidfilled latex balloon into the left ventricle through the mitral orifice and connected it to a Statham P23dB pressure transducer (Gould-Statham, Oxnard, Calif.). The balloon was filled with a volume of saline sufficient to produce an end-diastolic pressure of 10 mm Hg, which is on the plateau of the Starling curve for this preparation (data on file). All subsequent measurements were obtained at this same end-diastolic volume. Left ventricular pressure was recorded on a two-channel direct-writing recorder (Gould-Brush, Cleveland, Ohio). Developed pressure was calculated as the difference between peak systolic and end-diastolic pressures. Intermittent measurements of coronary flow were obtained with vacuum aspiration of perfusate overflow.
Experimental Protocol
Assessment of functional and metabolic recovery. After a 15-minute equilibration period, baseline functional parameters and two 5-minute phosphorus-31 NMR spectra were recorded. Total global ischemia was then induced by cross-clamping the perfusion line. During ischemia, the intraventricular balloon was deflated, and pacing was discontinued. Throughout the ischemic period, serial 5-minute NMR spectra were recorded. After 30 minutes of global ischemia, hearts were reperfused for 45 minutes. Pacing was resumed at the onset of reflow. After 15 minutes of reperfusion, the balloon was reinflated. Measurements of developed pressure and coronary flow were then made after 15, 30, and 45 minutes of reflow. Recovery of developed pressure and coronary flow were then expressed as a percentage of baseline values. Serial 5-minute NMR spectra were recorded throughout the reperfusion period.
Three experimental groups were studied: After 30 minutes of ischemia, a group of seven hearts (control) received a 10-ml bolus of standard perfusate during 30 seconds followed by standard reperfusion.
One group of nine hearts (reflow treated) received a 10-ml bolus of 5 mM deferoxamine during the initial 30 seconds of reflow, followed by constant infusion of 33 ml of 5 mM deferoxamine (total dose was 215 ,umol) during the first 15 minutes of reflow. A second group of nine hearts (ischemia treated) received a 43-ml bolus of 5 mM deferoxamine (total dose was 215 ,umol) during the initial 30 seconds of the 30minute ischemic period, followed by standard reperfusion. Preliminary studies revealed that this concentration of deferoxamine had no greater effect on left ventricular developed pressure than did the same volume bolus of standard perfusate at the same temperature.
Assessment of free radical concentrations. After a 15-minute equilibration period, a second set of hearts was subjected to 30 minutes of global ischemia. With Wollenberger tongs cooled to 77°K, hearts were freeze clamped either at the end of 30 minutes of ischemia or after 15 seconds of reperfusion. In a previous study, we showed that oxygencentered free radicals will increase from a baseline level of 1.0+0.4 to 4.0±1.0 ,uM after 30 minutes of ischemia before increasing rapidly to a peak level of 8.1±1.4 ,tM after 15 seconds of reflow.21 The freezeclamped hearts were ground to coarse powder under liquid nitrogen and were transferred to precision quartz EPR tubes. The internal diameter of the EPR tubes was 3 mm, and all tubes were filled to a height of 3 cm.
Control hearts received no treatment and were freeze clamped at end ischemia (n =5) or after 15 seconds of reperfusion (n=5). The reflow-treated hearts received a 10-ml bolus of 5 mM deferoxamine at the onset of reflow and were freeze clamped after 15 seconds of reperfusion (n=5). The ischemiatreated hearts received a 43-ml bolus of 5 mM deferoxamine at the onset of ischemia and were freeze clamped at end ischemia (n=5) or after 15 seconds of reflow (n=5). Methods of NMR spectroscopy. Phosphorus-3 1 NMR spectra were obtained with a WI 180 spectrometer (Bruker Instruments, Billerica, Mass.) at 4.2 T. At this field strength, phosphorus resonates at 72.89 MHz. The internal probe diameter was 25 mm. The pulsed Fourier transform mode was used, and the instrument was interfaced to a 1280 computer (Nicolet Instrument Corp., Madison, Wis.). Fiveminute spectra were collected from transients after 450 pulses delivered at 2-second intervals, which are conditions previously shown to result in minimal spectral saturation. 21 The data were accumulated with a 2K table at a 3,000-Hz spectral width. The spectra were plotted, and the areas under the phosphocreatine and ATP peaks were measured by graphic integration with a graphic tablet integrator (Hewlet-Packard, Palo Alto, Calif.). The quantitative results were expressed as a percentage of the preischemic baseline content. The pHi was calculated from the chemical shift of the inorganic phosphate peak relative to the chemical shift of the comparatively pH-insensitive phosphocreatine peak. 22 Methods of EPR spectroscopy. EPR spectra were recorded at a temperature of 77°K with an E-9 spectrometer (Varian Associates, Inc., Palo Alto, Calif.). Several different component signals were observed, including an oxygen-centered radical signal with axial symmetry that was observed with g,, = 2.033 and g, = 2.005, consistent with an alkyl peroxy radical (ROO.).8,23 Component signals were separated by computerized curve-fitting procedures.23 Quantitation was performed by comparison of the integrated signal area with that of the commonly used free radical standard potassium peroxylamine disulfonate in frozen aqueous solution in identical EPR tubes. Care was taken to use nonsaturating microwave power (1.0 mW). Microwave frequency was 9.278 GHz, and modulation amplitude was 2.5 G.
Chemicals
Deferoxamine methanesulphonate (Desferal, Ciba-Geigy, Basel), supplied as a lyophilized powder, was dissolved in warm oxygenated perfusate before use. Potassium peroxylamine disulfonate (Aldrich Chemical Co., Inc., Milwaukee, Wis.) and perfusate reagents (Sigma Chemical, Co., St. Louis) were all high-purity grade. Double-distilled, deionized water was used to prepare perfusate solutions.
Statistical Analysis
Data are mean±SEM. Comparisons of functional and metabolic parameters were made by two-way analysis of variance (ANOVA) designed for repeated measures. A probability level of less than 0.05 was considered significant. When the overall ANOVA revealed a significant interaction, individual comparisons for specific time points were tested with unpaired Student's t tests with p values corrected with the Bonferroni approach. Free radical concentrations were compared by two-tailed unpaired Student's t tests.
Results
Metabolic Data
Phosphocreatine content. Phosphocreatine content decreased rapidly in both control and reflow-treated hearts during the early minutes of ischemia, and the content for both reached a similar minimum level of 16% of baseline by 30 minutes of ischemia (p=NS) ( Figure 1 ). Although ischemia-treated hearts reached the same minimum level at 30 minutes of global ischemia as did control and reflow-treated hearts (p=NS), the timing of this early rapid decline in phosphocreatine content was delayed in ischemiatreated hearts (p<0.05 versus control hearts, p=NS versus reflow-treated hearts by ANOVA). Rapid recovery of phosphocreatine content was observed in all groups during the first 5-10 minutes of reflow. Although phosphocreatine content actually exceeded baseline content in both treatment groups by up to 35% during early reflow, control hearts never returned to baseline content. By 45 minutes of reflow, control hearts recovered only 68.2+4.5% of the preischemic phosphocreatine content, whereas reflow-treated hearts recovered 86.8+7.6% of the preischemic phosphocreatine content (p=0.05 by ANOVA). Recovery of phosphocreatine was slightly greater in ischemia-treated hearts, reaching 92.4±10.3%, at 45 minutes (p<0.05 versus control hearts, p=NS versus reflow-treated hearts). ATP content. ATP content decreased slowly and progressively during ischemia with a similar time course in all groups and reached a minimum of 32-45% of baseline by 30 minutes of ischemia (p=NS) (Figure 2 ). After reperfusion, ATP content remained at end-ischemic levels in control hearts (35. 6+2.6% at 45 minutes of reperfusion). In both treatment groups, ATP content tended to increase during reperfusion. ATP content in reflow-treated hearts recovered 47.2+4.1% of baseline by the end of reflow (p=NS versus control hearts by ANOVA). In the ischemia-treated group, ATP content recovered to 56.2+6.5% of baseline by 45 minutes of reflow. (p=NS versus control hearts by ANOVA).
pHi. The pHi decreased at a similar rate in control, reflow-treated, and ischemia-treated groups (p=NS by ANOVA), reaching similar minimum levels in all groups by 30 minutes of ischemia (control, 5.64±0.14; reflow-treated, 5.84+0.09; and ischemiatreated hearts, 5.90+0.08; Figure 3 ). After reflow, rapid return to near-baseline pHi occurred in all groups (p=NS by ANOVA). Data are plotted as mean +SEM and are compared by two-way analysis of variance. Hearts were given deferoxamine at onset of ischemia or as a bolus and 15-minute infusion at reflow. Control hearts received vehicle. pHi decreased in control hearts at a rate similar to that in both reflow-treated and ischemia-treated hearts (p=NS), andpHi reached similar end-ischemic values in all groups. After reflow, all groups recovered rapidly to near-normal pHi (p=NS). Coronary flow tended to be higher in both reflow-treated and ischemia-treated hearts than in untreated control hearts at all time points throughout the reperfusion period. However, this tendency did not reach significance (by ANOVA). By 45 minutes of reperfusion, coronary flow was 68.7±3.6% in the ischemia-treated, 69.6+4.9% in the reflow-treated, and 55.9+5.4% in control hearts (p=NS) ( Figure 5 ).
Free Radical Concentrations
Oxygen-centered free radicals were present at the end of 30 minutes of ischemia in a mean concentration of 4.2±0.6 ,uM ( Figure 6 ). The concentration of these radicals at end ischemia was not altered by the presence of deferoxamine during ischemia (4.1 ±0.5 ,uM, p=NS). An increase in free radical concentration occurred after 15 seconds of reperfusion in control hearts to 7.0±0.7 ,uM. Deferoxamine given during ischemia reduced the con- minutes of reperfusion. Baseline measurements were obtained just before cross clamping the perfusion line. Vertical dashed line denotes balloon reinflation. Data are plotted as mean +SEM and are compared by two-way analysis of variance. Hearts were given deferoxamine at onset of ischemia or as a bolus and 15-minute infusion at reflow. Control hearts received vehicle. Ischemia-treated hearts had a nonsignificant trend toward higher coronary flow compared with control hearts. Coronary flow after reperfusion in reflow-treated hearts was similar to that of ischemia-treated hearts and again was not significant compared with control hearts.
centration after 15 seconds of reflow to 2.9+0.1 ,uM. (p<0.001 versus control hearts). The reduction in oxygen free-radical concentration 15 seconds after reperfusion was similar when deferoxamine was administered beginning at the onset of reflow (2.4± 0.2 ,iM, p <0.001 versus control hearts, p =NS versus ischemia-treated hearts). Discussion This study demonstrates that administration of the iron chelator deferoxamine at the onset of global ischemia results in improvement of postischemic functional and metabolic recovery and in reduction of reperfusion-induced oxygen radical generation. Similar beneficial effects were obtained when deferoxamine was administered at the onset of reperfusion. In previous studies, deferoxamine was given either as a pretreatment before ischemia6 or at the onset of postischemic reperfusion as in a study from our laboratory.12 In the present study, intraischemic treatment with deferoxamine allowed us to evaluate more specifically the role of iron and iron chelation during the ischemic period.
Mechanisms of Reperfusion Injury
More than 15 years ago, the no-reflow phenome-non24,25 and calcium influx through abnormally "leaky" cell membranes26 were proposed as contributors to the myocardial injury observed after reperfusion of previously ischemic myocardium. More recently, the generation of oxygen free radicals was TREATMENT GROUP FIGURE 6. Bar graphs of oxygen-centered free radical concentrations. Panel A: Concentration of oxygen-centered free radicals at the end of 30 minutes ofglobal ischemia measured by electron paramagnetic resonance spectroscopy with the frozen tissue technique. Control hearts (n=5) were exposed to 30 minutes of 37°C global ischemia. Deferoxamine was given to ischemia-treated hearts at the onset of ischemia (n=5). Intraischemic treatment with deferoxamine did not alter the oxygen radical concentration at the end of ischemia: 4.2±0.6 ,M for control vs. 4.1 ±0.5 pM for ischemia treated hearts. Panel B: Concentration of oxygen-centered free radicals after 30 minutes ofglobal ischemia and 15 seconds of reperfusion. Ischemia-treated hearts (n=5) received a bolus of deferoxamine at the onset of ischemia only. Reflow-treated hearts (n=5) received a bolus of deferoxamine at the onset of reperfusion only. Hearts (n=5) receiving no treatment showed an increased concentration ofoxygen radicals after 15 seconds of reperfusion (7.0±0.7 pM). This increase was prevented by administration of deferoxamine during ischemia (2.9±0.1 gM, p<O.OOJ). The reduction in oxygen radical concentration was similar when deferoxamine was given at onset of reflow (2.4+0.2,M, p<0.001).
proposed as a more primary mechanism in the pathogenesis of "reperfusion injury." Support for the role of oxygen radicals in the pathogenesis of postisch-emic reperfusion damage comes from several lines of indirect evidence. Among the possible oxygen radicals involved, superoxide anion and the hydroxyl radical have received the most attention. Anti-free radical agents such as superoxide dismutase, catalase, allopurinol, and mannitol have protective effects on hearts of various animal species exposed to ischemia and reperfusion. In several studies, superoxide dismutase and superoxide dismutase plus catalase have reduced infarct size in animal models of acute myocardial infarction. [27] [28] [29] In contrast, other studies of superoxide dismutase with or without catalase have failed to confirm these beneficial effects on infarct size.3031 In a model analogous to that in the setting of clinical cardiac surgery, superoxide dismutase plus catalase have improved functional recovery after hypothermic global ischemia.3233 Blockade of superoxide radical production has been proposed as the mechanism of infarct size reduction by allopurinol. 27, 34 The hydroxyl radical scavenger mannitol has been shown by several investigative groups to improve recovery of global left ventricular function after hypothermic,35 hypothermic cardioplegic,3637 and normothermic ischemia.38 These beneficial effects were believed to be independent of a hyperosmolar mechanism.37 Likewise, another hydroxyl radical scavenger, dimethylthiourea, has improved the functional recovery after transient regional ischemia in a canine model. 3 Oxygen free radicals probably exert their damaging effect by disrupting membrane lipids or membrane-bound proteins. Burton et a14 have demonstrated vascular endothelial injury and mitochondrial swelling in both endothelial cells and myocytes after reperfusion. Other investigators have shown that concentrations of malonyldialdehyde, an end product of membrane lipid peroxidation, parallel quantitatively the functional damage occurring after postischemic reperfusion.39 However, the precise mechanisms whereby oxygen free radicals result in reperfusion-induced myocardial injury and the specific oxygen radical species responsible for this injury remain uncertain.
Role of Superoxide-Driven Fenton Chemistry
The superoxide radicals and the hydrogen peroxide formed during ischemia and reperfusion283940 have a relatively low cellular reactivity in the absence of a transition metal. 41 Thus, superoxide radicals and hydrogen peroxide may not be directly toxic. Instead, cellular injury is more likely related to subsequent generation of the more highly reactive hydroxyl radical by a sequence of reactions catalyzed by ferric iron.42 In fact, Gutteridge43 believes that only the hydroxyl radical has sufficient reactivity to abstract hydrogen atoms from unsaturated fatty acids within cell membranes. Superoxide radicals can, in theory, react directly with hydrogen peroxide to form the hydroxyl radical by the Haber-Weiss reaction: *2+H2O2-0 2+OH-+OH However, at physiological pH, the rate constant of this reaction is very slow compared with the two-step superoxide-driven Fenton reaction, which is catalyzed by ferric iron. 44, 45 In vitro evidence supporting a role for iron in the pathophysiology of cell-ular injury resulting from free radical generation cornes from Gutteridge et al, 46 who found that membrane phospholipid peroxidation in liposomes occurred only with the addition of iron to their free radical-generating system. These investigators then demonstrated that lipid peroxidation was inhibited by iron chelation with deferoxamine. Similarly, Starke and Farber47 demonstrated that damage to cultured hepatocytes was dependent on the presence of ferric iron in addition to superoxide and hydrogen peroxide and that removal of iron by chelation with deferoxamine prevented cell death. The improved myocardial functional and metabolic recovery obtained with the iron chelator deferoxamine in the present study support a role for Fenton chemistry in cardiac tissue in vivo as well.
Potential Sources of Iron in Ischemic Myocardium
Several potential sources of iron exist in ischemic myocardium to catalyze the superoxide-driven Fenton reaction in vivo. Perhaps the most abundant source of cellular iron is that bound to the large protein molecule ferritin. However, most intracellularly bound iron is in the ferric state. To be mobilized from ferritin, iron must first undergo reduction to the ferrous state. The superoxide anion has been shown in vitro to promote lipid peroxidation in liposomes in the presence of ferritin-bound iron, and this effect was blocked by addition of superoxide dismutase. 48 Thus, superoxide radicals formed during ischemia or at reflow may play a role in liberating iron from ferritin-bound stores in vivo.
Other changes occurring during ischemia may promote the release of iron from stable iron chelates to a free and, thereby, more reactive state. In vitro, iron bound to the serum protein transferrin is released when pH decreases from 7.4 to 5.7.49 Thus, the acidosis that accompanies ischemia may promote the availability of iron bound to transferrin in vivo. Other potential sources of iron include the cytochrome P-450 enzymes, hemoglobin, and myoglobin. Last, other investigators have postulated that iron delocalizes from normal intracellular binding sites to form "low molecular weight chelates" during ischemia. 50 Although the exact source of iron acting to catalyze hydroxyl radical generation during ischemia and reperfusion remains undefined, the heart is known to contain 96+35 ,ug iron/g tissue ash.51 Recently, rat hearts loaded with iron were shown to be more susceptible to ischemia and reperfusion injury than were control hearts. 52 In contrast, a deleterious effect of iron loading was not seen during normoxic perfusion. Furthermore, the iron-loaded hearts could be protected from ischemia and reperfusion injury by iron chelation. These results suggest that ischemia and reperfusion promote injury by generation of superoxide radicals, with the addition of excess iron promoting greater hydroxyl radical formation by superoxide-driven Fenton chemistry.
Characteristics of Deferoxamine
Deferoxamine is a naturally occurring iron chelator derived from Streptomycespilosus. It is a relatively low molecular weight protein (MW, 656.79) that is currently used clinically for treatment of iron-overload states. Several features of deferoxamine make it advantageous for studying the effects of iron chelation in the prevention of reperfusion injury. Deferoxamine has a very high binding affinity for iron (Kd= 1034) and is relatively selective for binding iron, with the next highest binding constant for other metals being lower by 107. Although deferoxamine cannot withdraw iron from heme or porphyrin molecules, it can extract iron from transferrin. 53 Several lines of evidence support the ability of deferoxamine to enter cells, which would allow it to also chelate intracellular iron. Pharmacokinetic studies show that the volume of distribution is greater than the extracellular fluid volume, with significant concentrations in tissues such as skeletal muscle.54 The drug has also chelated intracellular iron stored in the liver. 55 Furthermore, in isolated hepatocytes, preincubation with deferoxamine followed by cell washing prevented hydroxyl radical-mediated injury, implying that deferoxamine had entered the cells and chelated intracellular iron. 42 Although the present study does not provide direct evidence that deferoxamine acted at an intracellular site, its presence in the coronary vasculature during ischemia would have allowed sufficient time for equilibration of this small molecule to take place across the vascular interface and perhaps also across cell membranes.
Pathophysiological Implications
Phosphorus-31 NMR spectroscopy assured us that differences in functional recovery were not due to differences in the ischemic insult because all groups had similar end-ischemic phosphocreatine and ATP depletion and similar pHi. Hearts treated with deferoxamine either during ischemia or at reflow showed significantly greater recovery of phosphocreatine content than did control hearts, presumably the consequence of improved postischemic mitochondrial metabolism, with the degree of phosphocreatine recovery correlating well with the degree of functional recovery. Failure to demonstrate significant acute recovery of ATP content has been noted by US5 as well as other investigators,56-58 likely because of the loss of nucleotide bases during postischemic reperfusion.
EPR spectroscopy allowed us to measure directly the effect of deferoxamine administration on oxygen radical generation. As hypothesized, deferoxamine administration either during ischemia or during early reflow blunted the burst of free radical generation during the early seconds of reperfusion in the absence of deferoxamine. However, the presence of deferoxamine in the heart during ischemia did not result in a reduction in intraischemic oxygen freeradical generation. We speculate that the location of oxygen radicals generated during ischemia may be inaccessible to deferoxamine and different from the location of reperfusion-induced free radical generation. Alternatively, intraischemic radical generation may occur because of different mechanisms, which are not quenched by deferoxamine because either iron is not involved or the iron that is involved is present in a form, such as a hemeprotein, from which deferoxamine cannot extract iron.
Possible Clinical Implications
In the clinical setting of thrombolytic therapy for acute myocardial infarction, interventions aimed at preventing reperfusion injury can be initiated during the latter part of the ischemic period and then continued into the reperfusion period. In the clinical setting of elective cardiac surgery or cardiac transplantation, treatment can be started even earlier if desired. The results of the present study not only support a potential role for iron chelation in the prevention or reduction of oxygen radical-induced reperfusion injury but may also support initiation of therapy as early as possible so that the maximal potential benefit may be realized.
